MYADM and endocervical adenocarcinoma: After identifying MYADM as a potential biomarker for NSCLC, we analyzed the expression of MYADM in 31 other tumors, among these MYADM, was highly expressed in 6 tumors, including esophageal carcinoma, kidney renal clear cell carcinoma, acute myeloid leukemia pancreatic adenocarcinoma, stomach adenocarcinoma and testicular germ cell tumors, and lowly expressed in 6 tumors such as bladder urothelial carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, lymphoid neoplasm diffuse large B-cell lymphoma, thymoma, uterine corpus endometrial carcinoma, uterine carcinosarcoma.